Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.